Stablepharma are delighted to announce that Professor Saul Faust has accepted a position on Stablepharma’s Advisory Board. Professor Faust BMA, MBBS, FRCPCH, PhD, FHEA Professor or Paediatric Immunology and Infectious Diseases at the University of Southampton and Director of the NIHR Southampton Clinical Research Facility. He is currently leading the UK national 3rd dose COVID-19 vaccine booster trial.
‘Professor Faust is a fantastic addition to the Stablepharma’s Advisory Board, especially at a time when vaccine solutions are at the forefront of everyone’s mind,’ says Özgür Tuncer, CEO & Executive Director, Stablepharma Ltd.
Stablepharma’s novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. A stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world.
‘We are making significant progress with our Tetadif-Td programme in partnership with the European vaccine manufacturer BulBio, and we are now receiving very encouraging potency data from our animal challenge trials. This positive data has accelerated our plans to get Tetadif – StablevaX™ into first-in-human clinical trials. As a result, we are embarking on a Series A funding round in order to fund our upcoming clinical trials and scale up our GMP manufacturing’, added CEO Özgür Tuncer.
‘Our aim with the StablevaX™ invention is to ensure that most vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature’ says Dr Bruce Roser, Chairman & Founder, ‘having Professor Faust on our team will be a significant boost to our abilities’.
Nick Child, VP & Co Founder, Stablepharma added, ‘We are flattered that Professor Faust has agreed to join our Advisory Board as he brings with him significant expertise in designing and conducting first in human clinical trials, achievement of which is of course our end game for the StablevaX™ Td vaccine, hopefully the world’s first fridge free vaccine’.
Following the outstanding success of our recent £1.35m equity raise, StablePharma (www.stablepharma.com) is bringing a patented device to market that stands to significantly improve the way most vaccines are distributed globally, which will eliminate the current c. 50% wastage.
Now, that we have our first clinical trials in humans underway, Stablepharma is delighted to announce additional strategic roles to the board. The creation of a strong Leadership Team is of particular and timely significance to Stablepharma, as we grow and develop our business with the invention of the StablevaX™ brand, and its global positioning as a disrupter in the world of vaccination.